Home > Newsletters > Clinical Trials Advisor > FDA: Conduct Superiority Trials With PRO Endpoint for ABECB-COPD Drugs
Clinical Trials Advisor
Oct. 11, 2012 | Vol. 17 No. 20
FDA: Conduct Superiority Trials With PRO Endpoint for ABECB-COPD Drugs
Drugmakers should use superiority trials when developing antimicrobial drugs for the treatment of acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease (ABECB-COPD), according to an updated FDA guidance.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.